Marimed Stock Price, News & Analysis

MariMed, Inc. (OTCQX: MRMD) has filed a preliminary non-offering long form prospectus with securities regulatory authorities in Ontario and British Columbia. This Prospectus aims for a dual listing of its common shares on the Canadian Securities Exchange (CSE). CEO Robert Fireman expressed optimism about the potential listing, believing it will enhance liquidity and attract more retail and institutional investors. However, there is no guarantee of receiving final approval from regulators or the CSE.

MariMed, a leading multi-state cannabis operator, announced its participation in three upcoming cannabis conferences in April 2022. CEO Bob Fireman will engage in key discussions, including a fireside chat at the BTIG Global Cannabis Conference on April 6 at 1:50 PM ET. He will also join an Emerging MSO Panel at the Cantor Fitzgerald Cannabis Conference on April 13 at 9:00 AM ET, and participate in another fireside chat at the Benzinga Cannabis Capital Conference on April 20 at 1:15 PM ET. MariMed focuses on high-quality cannabis products and has seen consistent growth.

MariMed reported strong financial results for 2021, exceeding guidance with full-year revenue of $121.5 million (up 139% YoY) and adjusted EBITDA of $43.1 million (up 144% YoY). The fourth quarter revenue reached $31.0 million, driven by an 89% increase in retail operations. Gross profit for the year totaled $66.3 million, a 112% increase. Operational cash flow surged 961% year-over-year. Key strategic moves include acquisitions in Maryland and Illinois, plus a new cannabis beverage launch expected to enhance revenue growth.

MariMed, Inc. (OTCQX: MRMD) has launched Vibations: High + Energy, a new all-natural cannabis drink mix aimed at active users seeking focus and energy. The drink combines full-spectrum cannabis with guarana-based caffeine, vitamins, and electrolytes. Available in four flavors, it caters to health-conscious consumers with sugar-free options. The product will be sold in select Massachusetts dispensaries and will expand to Delaware and Maryland soon. This marks a strategic entry into the growing cannabis-infused beverage market.

MariMed, Inc. (OTCQX: MRMD) announced a definitive agreement to acquire a provisional dispensary license from Green House Naturals in Beverly, Massachusetts. This acquisition will add a second retail location under the Panacea Wellness brand, enhancing MariMed’s vertically integrated cannabis operations. The new dispensary is expected to open in the second half of 2022, aiming to strengthen the brand and contribute to revenue and Adjusted EBITDA growth. This move aligns with MariMed's strategic growth plan to deepen its market presence in high-growth states.

MariMed, Inc. (OTCQX: MRMD) will release its fourth quarter and full year 2021 financial results on March 16, 2022, after market close. A conference call to discuss these results is scheduled for March 17, 2022, at 8:00 a.m. ET. The call will be accessible via MariMed's Investor Relations website, where a playback will be available for 30 days. MariMed is recognized as a leading multi-state cannabis operator, focusing on high-quality products and consistent growth through its management team and proprietary formulations.

MariMed (OTCQX: MRMD) has expanded its reach into Delaware, where its cannabis brands are now available following new regulations in the state's Medical Marijuana program. The company has signed an enhanced licensing agreement with First State Compassion Center (FSC), allowing FSC to exclusively produce and distribute MariMed's popular cannabis edibles, including Betty’s Eddies® and Bubby’s Baked™. This expansion marks the availability of MariMed’s products in six states plus Puerto Rico, strengthening its market presence.

MariMed, Inc. (OTCQX: MRMD) has signed a definitive agreement to acquire Green Growth Group, Inc., holder of a provisional Cannabis Craft License in Illinois. This acquisition will enhance MariMed's cannabis operations in the state by integrating cultivation, manufacturing, and distribution capabilities. The transaction supports MariMed's strategy to improve revenue and profit margins by expanding in high-growth markets. Additionally, the company plans to develop a facility for cultivation and production of its proprietary cannabis products, leveraging Illinois's $1.8 billion cannabis market.